Antimicrobial activity of LysSS, a novel phage endolysin, against Acinetobacter baumannii and Pseudomonas aeruginosa.

Related Articles

Antimicrobial activity of LysSS, a novel phage endolysin, against Acinetobacter baumannii and Pseudomonas aeruginosa.

J Glob Antimicrob Resist. 2020 Jan 29;:

Authors: Kim S, Lee DW, Jin JS, Kim J

Abstract
OBJECTIVES: Multidrug-resistant (MDR) bacteria are a major concern in public health. Endolysins (lysins) from bacteriophage can be used as a novel antimicrobial agent against bacterial infectious diseases. In this study, a novel endolysin (LysSS) containing a lysozyme-like domain was evaluated for its antibacterial activity against various bacterial species.
METHODS: LysSS-encoding gene was analyzed and cloned and LysSS recombinant protein was expressed and purified. Purified LysSS was used to determine antimicrobial activities against various bacterial speciesin vitro and to measure its protection rate against Acinetobacter baumannii systemic infection model in vivo.
RESULTS: Recombinant LysSS showed activity against MDRAcinetobacter baumannii, MDR Escherichia coli, MDR Klebsiella pneumoniae, MDR Pseudomonas aeruginosa, and Salmonella without pretreatment with an outer membrane permeabilizer. Moreover, LysSS inhibited the growth of methicillin-resistant Staphylococcus aureus (MRSA). The minimum inhibitory concentration of LysSS against 16 strains of MDR Acinetobacter baumannii ranged from 0.063 to 0.25 mg/mL. LysSS had no cytotoxic effect on A549 human lung cells under 250 µg/mL. In an animal model, mice infected with A. baumannii were protected with a 40% survival rate by intraperitoneal injection of LysSS.
CONCLUSIONS: Our current results demonstrated that LysSS can be a novel and promising antimicrobial agent against MRSA and MDR Gram-negative bacteria includingA. baumannii and P. aeruginosa.

PMID: 32006750 [PubMed - as supplied by publisher]